Objective: This is a descriptive study to determine smoking prevalence rates in a convenience sample of patients with schizophrenia and to describe clinical/demographic variables for nicotine use in this population.
Method: Patients with schizophrenia were consecutively invited to answer a standard clinical/demographic questionnaire and a questionnaire on smoking habits (Fagerstrom Tolerance Questionnaire).
Results: Eighty-three patients were interviewed. The smoking rate was 57.8% (n = 48). Male (68.8%) patients smoked more than females did (31.3%; p = 0.081). Compared to patients who smoked at the time of disease onset, those who only started smoking after disease onset had a lower mean age at the time of disease onset [24 years old (SD = +/- 6.8) vs.19 years old (SD = +/- 3.9; p = 0.041)]. Patients who preferred high-nicotine content cigarettes (p < 0.01) had higher frequency of smoking inhalation (p < 0.05) and had more urgency to smoke the first cigarette in the morning (p < 0.05). Twenty-seven (56.3%) of smoking patients were heavy smokers (FTQ > or =8).
Conclusions: Patients with schizophrenia in our convenience sample smoked in a higher rate compared to the general population in Brazil. Smoking patients were heavy smokers evaluated by the Fagerstrom Tolerance Questionnaire.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/s1516-44462008005000014 | DOI Listing |
JMIR Ment Health
January 2025
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.
Background: Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic mental illnesses. CT-155/BI 3972080 is a prescription digital therapeutic under development as an adjunct to standard of care treatments for patients 18 years of age and older with experiential negative symptoms (ENS) of schizophrenia. Individual components of CT-155/BI 3972080 are designed based on the underlying principles of face-to-face treatment.
View Article and Find Full Text PDFBackground And Hypothesis: We have reported previously a reduction in superior temporal gyrus (STG) activation and in auditory verbal hallucinations (AHs) after real-time fMRI neurofeedback (NFB) in schizophrenia patients with AHs.
Study Design: With this randomized, participant-blinded, sham-controlled trial, we expanded our previous results. Specifically, we examined neurofeedback effects from the STG, an area associated with auditory hallucinations.
Schizophr Res Cogn
June 2025
Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, PR China.
Evidence suggests that attenuated mismatch negative (MMN) waves have a close link to auditory verbal hallucinations (AVH) and their clinical outcomes, especially impaired neural oscillations such as θ, β representing attentional control. In current study, thirty patients with schizophrenia and AVH (SZ) and twenty-nine healthy controls (HC) underwent multi-feature MMN paradigm measurements including frequency and duration deviant stimuli (fMMN and dMMN). Clinical symptoms and MMN paradigm were followed up among SZ group after 8-week treatment.
View Article and Find Full Text PDFSchizophr Res Cogn
June 2025
University Department of Child and Adolescent Psychiatry, Children's Hospitals of NICE CHU-Lenval, Nice, France.
Objective: To conduct a systematic review of neurocognitive dysfunctions in patients with childhood-onset schizophrenia (COS), a neuropsychiatric disorder that occurs before age 13 and is rarer and more severe than adult-onset schizophrenia.
Method: A search was made in the PubMed database. Sixty-seven studies (out of 543) which analyzed Intellectual Quotient (IQ), attentional, memory and executive functions were selected by two independent researchers.
Indian J Psychiatry
December 2024
Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Aim: This study aimed to evaluate the prevalence of obstructive sleep apnea (OSA) and its correlates among schizophrenia spectrum disorder patients receiving clozapine.
Methods: For this, 200 schizophrenia spectrum disorder patients receiving clozapine for at least one year were assessed on the Berlin Sleep Questionnaire for OSA.
Results: Around one-sixth of the study sample (16.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!